IMMUNOLOGY2026™ Conference Recordings For Attendees-Resolvins and novel pro-resolving agonists in the resolution of inflammation

Video Transcription

Video Summary

Charles Serhan opened the symposium by presenting the concept of “resolution medicine,” arguing that inflammation is not only driven by classic pro-inflammatory mediators like prostaglandins and leukotrienes, but also actively ended by endogenous specialized pro-resolving mediators (SPMs). His group identified major SPM families—resolvins, lipoxins, protectins, and maresins—through lipidomics and structural synthesis.  <br /><br />He explained that these mediators stop neutrophil infiltration, promote macrophage clearance of dead cells and microbes, reduce pain, and restore tissue homeostasis without causing immune suppression. SPMs act through specific GPCRs and can also influence adaptive immunity, wound healing, organ protection, and even cancer and infection outcomes.  <br /><br />A major theme was that chronic inflammatory diseases often reflect impaired resolution, and that boosting SPM pathways may offer safer therapies than traditional anti-inflammatory drugs. Serhan also described new findings from human saliva, including a D2-like resolvin epimer and a longer-acting synthetic mimetic with strong pro-resolving activity.  <br /><br />He concluded that resolution is an active, coordinated process controlled by the body’s own mediators, and highlighted early human trials showing promise in dry eye and periodontal disease.

Meta Tag

Date April 19, 2026 8:00 AM - 8:38 AM

Room Ballroom

Session Major Symposium H: Resolution of Inflammation

Speaker Charles Serhan

Track Cellular Adhesion, Migration, and Inflammation (CAM)

Year 2026

Keywords

resolution medicine

specialized pro-resolving mediators

resolvins

lipoxins

maresins

inflammation resolution

GPCR signaling

April 19, 2026 8:00 AM - 8:38 AM

Ballroom

Major Symposium H: Resolution of Inflammation

Charles Serhan

Cellular Adhesion, Migration, and Inflammation (CAM)

2026